The overall goal of the University of Pennsylvania Udall Center is to address the problem of cognitive impairment in Parkinson's Disease (PD) from bench to bedside. This project contributes to that goal by developing a disease-specific rating scale to measure the impact that cognitive impairment has on daily function. The scale would be appropriate for use in patients with PD and dementia (PDD) and also for patients with PD and cognitive impairments not sufficient to meet diagnostic criteria for PDD. Our proposed rating scale is intended to be an outcome measure for observational studies and clinical trials. There is currently no disease-specific scale to address the impact that cognitive impairment has on daily function in PD, and clinical trials to date have borrowed functional measures developed for use in Alzheimer's disease (AD). However, the cognitive profile of patients with PD is distinct from AD. In addition, patients with PD have motor impairments that affect their daily, function, and may obscure the impact of cognitive impairment as measured by existing scales used in dementia research. Thus, there is a need for a functional rating scale specifically for use in PD patients with cognitive impairment. We propose to develop a new scale, the """"""""Functional Consequences of Cognitive Impairment"""""""" (FCCI) scale to address this unmet need. We will take a methodologically rigorous approach to scale development beginning with detailed qualitative studies to generate scale items, followed by psychometric studies to demonstrate the reliability and validity of the FCCI.
The first aim of this study is to conduct qualitative studies involving patients and knowledgeable informants to generate a range of items addressing the functional consequence of cognitive impairment that will be used to create the final rating scale.
The second aim of this study is to undertake detailed psychometric testing of the reliability and internal consistency of the FCCI.
The third aim i s to assess the validity, test-retest reliability and responsiveness to change of the FCCI in a longitudinal cohort study of patients with PD. The product of our study will be a reliable and valid measure of the impact of cognitive impairmen on basic and instrumental aspects of daily function. We hypothesize that our new instrument will capture the impact of cognitive impairment on daily function to a greater extent than existing scales used in PD and dementia research. Over the course of the project, we will gain valuable insights into the rate of progression of functional impairment in PDD, and the relative contributions of motor and non-motor features of PD to function over time.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
1P50NS053488-01A2
Application #
7246774
Study Section
Special Emphasis Panel (ZNS1-SRB-E (21))
Project Start
Project End
Budget Start
2007-06-15
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$269,283
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Rennert, Lior; Xie, Sharon X (2018) Cox regression model with doubly truncated data. Biometrics 74:725-733
Peng, Chao; Gathagan, Ronald J; Lee, Virginia M-Y (2018) Distinct ?-Synuclein strains and implications for heterogeneity among ?-Synucleinopathies. Neurobiol Dis 109:209-218
Blue, Elizabeth E; Bis, Joshua C; Dorschner, Michael O et al. (2018) Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. Dement Geriatr Cogn Disord 45:1-17
Holden, Samantha K; Medina, Luis D; Hoyt, Brian et al. (2018) Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. Mov Disord 33:1760-1768
Barupal, Dinesh Kumar; Fan, Sili; Wancewicz, Benjamin et al. (2018) Generation and quality control of lipidomics data for the alzheimer's disease neuroimaging initiative cohort. Sci Data 5:180263
Mantri, Sneha; Fullard, Michelle; Gray, Shelly L et al. (2018) Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. JAMA Neurol :
Olm, Christopher A; McMillan, Corey T; Irwin, David J et al. (2018) Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. Neuroimage Clin 19:497-506
Sandelius, Åsa; Portelius, Erik; Källén, Åsa et al. (2018) Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimers Dement :
Henderson, Michael X; Peng, Chao; Trojanowski, John Q et al. (2018) LRRK2 activity does not dramatically alter ?-synuclein pathology in primary neurons. Acta Neuropathol Commun 6:45
Chahine, L M; Dos Santos, C; Fullard, M et al. (2018) Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. Eur J Neurol :

Showing the most recent 10 out of 339 publications